Academic discussion/ Lecture class for 5th year MBBS students on Diabetic Emergencies, types, their sign-symptoms and managements. Most of the Data was taken from Davidson's Principles and Practice of Medicine.
Academic discussion/ Lecture class for 5th year MBBS students on Diabetic Emergencies, types, their sign-symptoms and managements. Most of the Data was taken from Davidson's Principles and Practice of Medicine.
Many have troubles choosing the proper insulin type and dosing for their patients.. Here is a quick presentation that introduce you to different studies in that matter.
This presentation is intended for healthcare prfessionals
MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of...Dr. Om J Lakhani
Talk on MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of Metformin In CKD).
Presented on 25th June 2017 at THE METFORMIN MEET in Vadodara, India
Acute kidney injury (AKI) is a potentially life-threatening
syndrome that occurs primarily in hospitalized patients
and frequently complicates the course of critically ill
patient.
Acute Kidney Injury is is (abrupt) reduction in kidney functions as evidence by changed in laboratory values; serum creatinine, blood urea nitrogen(BUN)and urine output
Diabetes mellitus (DM) has routinely been described as a metabolic disorder characterized by hyperglycemia that develops as a consequence of defects in insulin secretion, insulin action, or both.
Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body's systems, in particular the blood vessels and nerves.
1. Microvascular (due to damage to small blood vessels).
2. Macrovascular (due to damage to larger blood vessels).
Management of hypertensive condition in 2020 according to AHA/ASA guidelines. We will discuss the presentation, clinical assessment, investigations, and management of hypertension along with major randomized controlled trials and guidelines.
Many have troubles choosing the proper insulin type and dosing for their patients.. Here is a quick presentation that introduce you to different studies in that matter.
This presentation is intended for healthcare prfessionals
MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of...Dr. Om J Lakhani
Talk on MANAGEMENT OF DIABETES IN CHRONIC KIDNEY DISEASE (Special reference to Use of Metformin In CKD).
Presented on 25th June 2017 at THE METFORMIN MEET in Vadodara, India
Acute kidney injury (AKI) is a potentially life-threatening
syndrome that occurs primarily in hospitalized patients
and frequently complicates the course of critically ill
patient.
Acute Kidney Injury is is (abrupt) reduction in kidney functions as evidence by changed in laboratory values; serum creatinine, blood urea nitrogen(BUN)and urine output
Diabetes mellitus (DM) has routinely been described as a metabolic disorder characterized by hyperglycemia that develops as a consequence of defects in insulin secretion, insulin action, or both.
Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body's systems, in particular the blood vessels and nerves.
1. Microvascular (due to damage to small blood vessels).
2. Macrovascular (due to damage to larger blood vessels).
Management of hypertensive condition in 2020 according to AHA/ASA guidelines. We will discuss the presentation, clinical assessment, investigations, and management of hypertension along with major randomized controlled trials and guidelines.
In this presentation students will have the opportunity to learn all definitions and acronyms related to patient assessment. We have links to YouTube videos to further demonstrate various assessments.
Infertility is defined as the inability of a couple to conceive after at least one year of regular unprotected intercourse.
Male infertility refers to a male's inability to cause pregnancy in a fertile female.
IDD situation in our country has improved
A good number of thyroid disorder patients are either undiagnosed and or untreated
Thyroid disorder in pregnancy- Rate high
As a sound thyroid functioning status is crucial for growth, development in children; reproduction, psychological and general wellbeing in adults, we must be proactive in screening, diagnosing and treating our patients.
Over the past several years it has been proved that maternal thyroid disorder influence the outcome of mother and fetus, during and also after pregnancy. The most frequent thyroid disorder in pregnancy is maternal hypothyroidism. It is associated with fetal loss, placental abruptions, pre-eclampsia, preterm delivery and reduced intellectual function in the offspring.1 In pregnancy, overt hypothyroidism is seen in 0.2% cases2 and sub clinical hypothyroidism in 2.3% cases3. Fetal loss, fetal growth restriction, pre-eclampsia and preterm delivery are the usual complications of overt hyperthyroidism (low TSH and high T3, T4) seen in 2 of 1000 pregnancies whereas mild or sub clinical hyperthyroidism (suppressed TSH alone) is seen in
1.7% of pregnancies and not associated with adverse outcomes4. Autoimmune positive euthyroid pregnancy shows doubling of incidence of miscarriage and preterm delivery. Worldwide more than 20 million people develop neurological sequel due to intra uterine, iodine deprivation5. Other problems of thyroid disorders in pregnancy are post partum thyroiditis, thyroid nodules and cancer, hyper emesis gravidarum etc. Debates and disputes persist regarding several protocol and management plan in this specific spectrum of diseases.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
2. Issues in the Management of
Type 2 Diabetes
• Type 2 DM is a chronic condition with
progressive loss of beta-cell function over time
• Increasing prevalence with obesity
• Hyperglycemia affects morbidity, mortality
• Tight glycemic control with insulin may reduce
costly complications
2
3. 3
• 30% to 40% of patients ultimately require
insulin.
• Newer semisynthetic or analog insulins
and delivery systems may improve
compliance and achieve better glycemic
control with less hypoglycemia.
…………………Conted
4. Defined glycemic targets in T2DM
PG=plasma glucose.
1. American Diabetes Association. Diabetes Care 2005;28(suppl 1):S14—36.
2. American Association of Clinical Endocrinologists. Endocr Pract 2002;8(suppl 1):43—84.
3. International Diabetes Federation. Diabet Med 1999;16:716—30.
*1−2 hours postprandial; **2 hours postprandial.
Glucose control Healthy ADA1
AACE2
IDF3
HbA1c (%) <6 <7 ≤6.5 ≤6.5
Mean FPG
mmol/l (mg/dl)
<5.6
(<100)
5−7.2
(90−130)
<6
(<110)
<6
(<110)
Mean
postprandial PG
mmol/l (mg/dl)
<7.8
(<140)
<10*
(<180)
<7.8**
(<140)
<7.5**
(<135)
4
5. The Goal of Insulin Therapy:
Attempt to Mimic Normal Pancreatic Function
Schade, Skyler, Santiago, Rizza, “Intensive Insulin Therapy,” 1993, p. 131.
0
6 0
3 0
1 0 0
6 0
1 4 0
1 5
1 9 3 0
H O U R S
2 3 3 0 0 3 3 0 0 7 3 01 5 3 01 1 3 03 3 0
8 0
4 0
1 2 0
7 5
1 6 0
P L A S M A
G L U C O S E
m g / d l
B L S H S
P L A S M A F R E E
IN S U L IN
u / m l
6. Purpose of Insulin Therapy
• Prevent and treat fasting and postprandial
hyperglycemia
• Permit appropriate utilization of glucose and
other nutrients by peripheral tissues
• Suppress hepatic glucose production
• Prevent acute complications of uncontrolled
diabetes
• Prevent long term complications of chronic
diabetes 6
7. All type 1 diabetics should be on a
Bolus-bolus insulin regimen to
control glucose while minimizing
hypoglycemia.
6-19
8. However over time, most type 2
diabetics will also need both basal
and mealtime insulin to control
glucose.
6-19
10. Patient Concerns About Insulin
• Fear of injections
• Perceived significance of need for insulin
• Worries that insulin could worsen diabetes
• Concerns about hypoglycemia
• Complexity of regimens
10
11. When to Start Insulin?
• Watch for the following signs
– Increasing BG levels
– Elevated A1C
– Unexplained weight loss
– Traces of ketonuria
– Poor energy level 11
When OHAs are not enough to achieve
target glycemic status --
12. …..When Oral Medications Are Not Enough
– Sleep disturbances
– Polydipsia
• Next steps
– Make a decision to start insulin
– Offer patient encouragement, not blame
12
13. …..Initiating Insulin Therapy in Type 2 Diabetes
• Let blood glucose levels guide choice
of insulins
– Select type(s) of insulin and timing
of injection(s) based on pattern of
patient’s sugar (fasting, lunch,
dinner, bedtime)
13
14. ….Initiating Insulin Therapy in Type 2 Diabetes
• Choose from currently available insulin
preparations
– Rapid-acting (mealtime): lispro, aspart,
glulisine
– Short-acting (mealtime): regular insulin
– Intermediate-acting (background): NPH,
lente
– Long-acting (background): degledec,
ultralente, glargine
– Insulin mixtures (premixed)
15. ….Initiating Insulin Therapy in Type 2 Diabetes
• Provide long-acting or intermediate-
acting as basal and rapid-acting as bolus
• Titrate every week
Goal: to approximate endogenous insulin secretion…
16. The ADA TreatmentThe ADA Treatment
Algorithm for the Initiation andAlgorithm for the Initiation and
Adjustment of InsulinAdjustment of Insulin
16
17. Step One: Initiating InsulinStep One: Initiating Insulin
• Start with either…
– Bedtime long-acting/intermediate acting
insulin
Insulin regimens should be designed taking
lifestyle and meal schedules into account
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.17
18. Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d
• Check fasting glucose and increase dose
until in target range
– Target range: 3.89-7.22 mmol/l (70-130 mg/dl)
– Typical dose increase is 2 units every 3 days,
but if fasting glucose >10 mmol/l (>180 mg/dl),
can increase by large increments (e.g., 4 units
every 3 days).
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.18
19. • If hypoglycemia occurs or if fasting glucose
>3.89 mmol/l (70 mg/dl)…
– Reduce bedtime dose by ≥4 units or 10%
if dose >60 units
Step One: Initiating InsulinStep One: Initiating Insulin, cont’d, cont’d
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.19
20. • If HbA1c is <7%...
– Continue regimen and check HbA1c every
3 months
• If HbA1c is ≥7%...
– Move to Step Two…
After 2-3 Months…After 2-3 Months…
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.20
21. Initiating and Adjusting InsulinInitiating and Adjusting Insulin
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime intermediate-acting insulin, or
bedtime or morning long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
If HbA1c ≤7%... If HbA1c ≥7%...
21
22. Step One…
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
22
23. Step Two: Intensifying InsulinStep Two: Intensifying Insulin
If fasting blood glucose levels are in target
range but HbA1c ≥7%, check blood glucose
before lunch, dinner, and bed and add a
second injection:
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.23
24. Step Two: Intensifying InsulinStep Two: Intensifying Insulin
• If pre-lunch blood glucose is out of range,
add rapid-acting insulin at breakfast
• If pre-dinner blood glucose is out of range,
add NPH insulin at breakfast or rapid-
acting insulin at lunch
• If pre-bed blood glucose is out of range,
add rapid-acting insulin at dinner
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.24
25. Insulin AdjustmentsInsulin Adjustments
• Can usually begin with ~4 units and
adjust by 2 units every 3 days until
blood glucose is in range.
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.25
26. • If HbA1c is <7%...
– Continue regimen and check HbA1c every
3 months
• If HbA1c is ≥7%...
– Move to Step Three…
After 2-3 Months…After 2-3 Months…
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.26
27. Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Step Two…
Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
27
28. Step Three:Step Three:
Further Intensifying InsulinFurther Intensifying Insulin
• Recheck pre-meal blood glucose and
if out of range, may need to add a third
injection:
• If HbA1c is still ≥ 7%
–Check 2-hr postprandial levels
–Adjust preprandial rapid-acting insulin
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.28
29. Nathan DM et al. Diabetes Care. 2006;29(8):1963-72.
Continue regimen; check
HbA1c every 3 months
If fasting BG in target range, check BG before lunch, dinner, and bed.
Depending on BG results, add second injection
(can usually begin with ~4 units and adjust by 2 units every 3 days until BG in range)
Recheck pre-meal BG levels and if out of range, may need to add another
injection; if HbA1c continues to be out of range, check 2-hr postprandial levels
and adjust preprandial rapid-acting insulin
If HbA1c ≤7%...
Bedtime long-acting insulin
(initiate with 10 units or 0.2 units per kg)
Check FG and increase dose until in target range.
If HbA1c ≥7%...
Hypoglycemia
or FG >3.89 mmol/l (70 mg/dl):
Reduce bedtime dose by ≥4 units
(or 10% if dose >60 units)
Pre-lunch BG out of range: add
rapid-acting insulin at breakfast
Pre-dinner BG out of range: add NPH insulin at
breakfast or rapid-acting insulin at lunch
Pre-bed BG out of range: add
rapid-acting insulin at dinner
Continue regimen; check
HbA1c every 3 months
Target range:
3.89-7.22 mmol/L
(70-130 mg/dL)
If HbA1c ≤7%... If HbA1c ≥7%...
Step Three…
29
30. Premixed InsulinPremixed Insulin
• Not recommended during dose
adjustment .
• Can be used before breakfast and/or
dinner if the proportion of rapid- and
intermediate-acting insulin is similar
to the fixed proportions available
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.30
31. Basal Insulins in Type 2 DM
• NPH at HS - duration of action short:
- usually need AM injection
- nighttime hypoglycemia a
problem
31
32. Basal Insulins in Type 2 DM
• Analogs
- Degludec - true once daily injection
- Glargin - likely to succeed as true once
daily injection
- Detemir – Basal insulin
32
33. Inhaled InsulinInhaled Insulin
• Approved in the U.S. in 2006 for the
treatment of type 2 diabetes and then had
been withdrawn from the market.
• In June, 2014 another inhaled insulin
(Afreeza) got US FDA approval and Aventis
bought the patent of it for commercial
production and marketing.
Nathan DM et al. Diabetes Care 2006;29(8):1963-72.33
35. Need of Changing Insulin Regimen
• Failure to attain or maintain target
glycemic status (FPG/PPG or HbA1C).
• H/O repeated hypoglycemia
• Lifestyle issues
36. Changing from Other regimens to
Basal/Bolus Insulin
~50%
Basal*
Total Daily DoseTotal Daily Dose
(~70-75% of prior insulin regimen TDD)(~70-75% of prior insulin regimen TDD)
~50%
Bolus*
Usually divided into 3 premealUsually divided into 3 premeal
dosesdoses*Range: 40 to 60%*Range: 40 to 60%
37. An Example:
• Mr. M: 58 yrs with history type 2 diabetes for
8 years
– In addition to OHAs, he is on 70/30 premixed
insulin: 30 u AM and 15 u PM
– Current Total Daily Dose = 45 u of 70/30
– However, he has been having difficulty with
wide glycemic excursions.
38. ………….An Example:
• After discussing his options in detail, he
is willing to begin with basal/bolus
regimen:
• New TDD= 45 u x .75 = 33.75 = 34 u
– Basal = 17 u Degludec at bedtime
– Bolus = 17 u total / 3 = 5.6 u = 5 u
aspart/Glulisine immediately before meals.
39. Another method
• Same patient: Mr. M on 70/30 insulin:
30 u AM and 15 u PM
– Current Total Daily Dose = 45 u of 70/30
• Instead, some clinicians prefer to
instead calculate the new basal/bolus
doses independently of each other
– Current Basal= 0.70 x 45 u TDD = 31.5 u N
– Current Bolus= 0.30 x 45 u TDD = 13.5 u.
40. ………….Another method
• Then, use 70 to 75% of prior NPH,
but divide prior short acting into 3
premeal doses
– New Basal= 0.75 x 31.5 u N = 24 u
Degludec, Glargine, Detemir.
– New Bolus= 13.5 u R / 3 = 4.5 u (round up
or down) Aspart or Glulisine
41. So which method is best?
• This is where the “Art of Medicine”
comes in:
– If patient has been having difficulty with
hypoglycemia, then start any new insulin
regimen with conservative doses.
– If patient, on the other hand, has been having
hyperglycemia, then one can be more
aggressive.
Remember: every patient is an individual!
42. A Quick Word on using Sliding
Scale Insulin….
Don’t!
43. Instead of Sliding Scale....
• Basal insulin is necessary even in the fasting
state
• Sliding scales do not provide physiologic insulin
needs
• Sliding scales often result in “chasing” of
blood sugars
• There can be wide glycemic excursions
Remember: Just because a diabetic’s FBG is <150 does not mean
that they need no insulin!
Think Supplementation or Correction Scale…
44.
45. The Solution:
• In acutely ill hospitalized diabetics:
use continuous IV insulin
46. ………The Solution:
• If one must use an insulin scale in an outpatient or
stable inpatient setting:
• Insulin scale should only supplement a routine
scheduled regimen of basal and premeal insulin
• May use to correct for hyperglycemia between
scheduled doses of insulin
• It should NEVER be ordered such that the scale is
the only source of insulin for the patient
47. Drawbacks of intensive
insulin regimens
• Requires frequent monitoring of glucose
• Multiple daily injections of insulin
• Requires intensive patient education/on-
going support
• Newer insulin analogues require less
injections a but are more expensive 47
48. Key Take-Home MessagesKey Take-Home Messages
• Insulin is the oldest, most studied, and most
effective antihyperglycemic agent, but can
cause weight gain (2-4 kg) and
hypoglycemia.
• Insulin analogues with longer, non-peaking
profiles may decrease the risk of
hypoglycemia compared with NPH insulin.
48
49. Key Take-Home MessagesKey Take-Home Messages
• Premixed insulin is not recommended
during dose adjustment.
49
50. Key Take-Home MessagesKey Take-Home Messages
• When initiating insulin, start with bedtime
or morning long-acting insulin.
• After 2-3 months, if FBG levels are in
target range but HbA1c ≥7%, check BG
before lunch, dinner, and bed,
and, depending on the results, add 2nd
injection.
50
51. Key Take-Home MessagesKey Take-Home Messages
• After 2-3 months, if pre-meal BG out of
range, may need to add a 3rd
injection; if
HbA1c is still ≥7% check 2-hr postprandial
levels and adjust preprandial rapid-acting
insulin.
• Adjust one insulin at a time. Begin with the
insulin that will correct the first problem
blood glucose of the day.
51
52. Key Take-Home MessagesKey Take-Home Messages
• It is difficult to obtain optimal control
without occasional, mild episodes of
hypoglycemia.
52
Slide 6-19
MIMICKING NATURE WITH INSULIN THERAPY
Over time, most patients will need both basal and mealtime insulin to control glucose
Since both fasting and postprandial glucose levels are abnormal in type 2 diabetes and the underlying insulin deficiency typically progresses, most patients will need both basal insulin and mealtime insulin if excellent glucose control is to be maintained. The goal of intensive insulin therapy is to delay the onset of microvascular complications and retard their progression once they occur.
Slide 6-19
MIMICKING NATURE WITH INSULIN THERAPY
Over time, most patients will need both basal and mealtime insulin to control glucose
Since both fasting and postprandial glucose levels are abnormal in type 2 diabetes and the underlying insulin deficiency typically progresses, most patients will need both basal insulin and mealtime insulin if excellent glucose control is to be maintained. The goal of intensive insulin therapy is to delay the onset of microvascular complications and retard their progression once they occur.
Slide 6-36
Overcoming Complexity by Starting With Basal Insulin
One way to overcome the complexity of multiple daily insulin injection regimens is to start with basal insulin in patients with type 2 diabetes who are no longer responding adequately to oral agents.
As described, patients often proceed from taking a single oral medication to taking 2 or more oral agents or a combination of oral medication with insulin. Commonly, insulin is initiated in a schedule with intermediate- or long-acting insulin at bedtime to control fasting glucose levels and oral medications to control daytime glucose levels.
As described, patients often proceed from taking a single oral medication to taking 2 or more oral agents or a combination of oral medication with insulin. Commonly, insulin is initiated in a schedule with intermediate- or long-acting insulin at bedtime to control fasting glucose levels and oral medications to control daytime glucose levels.
Key Point
When initiating insulin, the ADA recommends beginning with either a bedtime intermediate-acting insulin or a bedtime or morning long-acting insulin. This can be initiated with 10 units or 0.2 units per kilogram.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
Fasting glucose should be checked daily via fingerstick and the dose should be increased, typically by 2 units every 3 days, until fasting levels are in the target range (i.e., 3.89-7.22 mmol/l or 70-130 mg/dl).
If fasting glucose is over 10 mmol/l (i.e., over 180 mg/dl), doses can be increased in larger increments (for example, by 4 units every 3 days).
All insulin regimens should be designed to take lifestyle and meal schedules into account.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
HbA1c should be re-checked within 2 to 3 months.
If it is below 7%, the current regimen should be continued with re-evaluation of HbA1c levels every 3 months.
If it is 7% or higher, physicians should move to Step Two of the algorithm.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
Although initial therapy is aimed at increasing basal insulin supply, usually with intermediate- or long-acting insulin, patients may also require prandial therapy with short- or rapid-acting insulin as well. The ADA algorithm has been created to help guide physicians in determining a patient’s optimal insulin regimen.
There are three steps to the algorithm. Each will be reviewed in turn.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Point
Step one involves initiating insulin.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
If, after 2 to 3 months of initiating insulin therapy, fasting blood glucose levels are in target range but HbA1c is 7% or higher, the patient’s blood glucose should be checked before lunch, dinner, and bed, and a second injection should be added.
If the patient’s pre-lunch blood glucose is out of range, rapid-acting insulin should be added at breakfast.
If pre-dinner blood glucose is out of range, NPH insulin should be added at breakfast or rapid-acting insulin should be added at lunch.
If pre-bed blood glucose is out of range, rapid-acting insulin should be added at dinner.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
If, after 2 to 3 months of initiating insulin therapy, fasting blood glucose levels are in target range but HbA1c is 7% or higher, the patient’s blood glucose should be checked before lunch, dinner, and bed, and a second injection should be added.
If the patient’s pre-lunch blood glucose is out of range, rapid-acting insulin should be added at breakfast.
If pre-dinner blood glucose is out of range, NPH insulin should be added at breakfast or rapid-acting insulin should be added at lunch.
If pre-bed blood glucose is out of range, rapid-acting insulin should be added at dinner.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
Again, HbA1c should be re-checked within 2 to 3 months.
If it is below 7%, the current regimen should be continued with re-evaluation of HbA1c levels every 3 months.
If it is 7% or higher, physicians should move to Step Three of the algorithm.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Point
Step Two of the algorithm involves intensifying insulin therapy.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for
the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
If pre-meal blood glucose is out of range when rechecked, a third injection of insulin may be needed.
If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Point
Step Three of the algorithm involves further intensifying insulin therapy.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm
for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
Premixed insulin is not recommended during dose adjustment.
However, it can be used conveniently, usually before breakfast and/or dinner, if the proportion of rapid- and intermediate-acting insulin is similar to the fixed proportions available.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
Inhaled insulin was approved in the U.S. in 2006 for the treatment of type 2 diabetes.
However, published clinical studies to date have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower, either as monotherapy or in combination with an injection of long-acting insulin.
Reference:
Nathan DM et al. Management of hyperglycemia in type 2 diabetes: a consensus
algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29(8):1963-72.
Key Points
In conclusion:
Insulin is the oldest, most studied and most effective antihyperglycemic agent but can cause weight gain (2-4 kg) and, in rare instances, hypoglycemia
Insulin analogues with longer, non-peaking profiles may decrease the risk of hypoglycemia compared with NPH insulin
Published studies have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower
Premixed insulin is not recommended during dose adjustment
Key Points
In conclusion:
Insulin is the oldest, most studied and most effective antihyperglycemic agent but can cause weight gain (2-4 kg) and, in rare instances, hypoglycemia
Insulin analogues with longer, non-peaking profiles may decrease the risk of hypoglycemia compared with NPH insulin
Published studies have not demonstrated whether inhaled insulin can lower HbA1c to 7% or lower
Premixed insulin is not recommended during dose adjustment
Key Points
(continued from previous):
When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin
After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added.
After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.
Key Points
(continued from previous):
When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin
After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added.
After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.
Key Points
(continued from previous):
When initiating insulin, patients should start with bedtime intermediate-acting insulin, or bedtime or morning long-acting insulin
After 2 to 3 months, if fasting blood glucose levels are in target range but HbA1c is 7% or higher, blood glucose levels should be checked before lunch, dinner and bed, and, depending on the results, a 2nd insulin injection should be added.
After 2 to 3 months, if pre-meal blood glucose is out of range, a 3rd injection may be needed. If HbA1c is still 7% or higher, 2-hour postprandial levels should be checked and preprandial rapid-acting insulin adjusted accordingly.